Ignite Creation Date:
2025-12-24 @ 9:28 PM
Ignite Modification Date:
2025-12-28 @ 12:11 AM
Study NCT ID:
NCT03713632
Status:
COMPLETED
Last Update Posted:
2024-10-09
First Post:
2018-10-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
Sponsor:
Novartis Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CAIN457M2302
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None